ClexBio Logo
engineering human tissue implants
Advanced Therapies Congress London 2022

Chronic venous insufficiency (CVI)

2.5m patients in the US alone suffer from severe CVI due to reflux

$30b annual wound care costs in the US, on average $30k per patient and year

40% more work-days missed than healthy people

20% - 40% 1-year ulcer recurrence - continuous treatment needed

No effective treatment options to date

Tissue-engineered vein grafts

ClexBio’s solution: Tissue-engineered human vein grafts

Biocompatible: Final product consisting of extracellular matrix (ECM) produced by healthy human cells

Functional: Grafts have functional bi-cuspal valves and optimal mechanical properties mimicking real veins
Allogeneic: Cells are removed, resulting in non-immunogenic graft for transplant to any CVI patient

Scalable: Manufacturing process can be parallelized and scaled to meet global demand

Permanent: Eliminate reflux and  permanently treat CVI

The VivoSetTM technology

VivoSet is a technology that utilizes healthy human cells to grow tissues composed of extracellular matrix . The uniqueness of VivoSet is the ability to grow large tissues rapidly in any chosen geometry, e.g. veins and other conduits.

VivoSet's USPs:
1) Recreate complex tissue geometries
2) Macroscopic dimensions (~cm, not limited by diffusion barrier of 100 um)
3) Fast tissue formation
4) Mechanically strong
5) Scalability of formulation

Partners & Supporters

Featured in


We are currently looking for globally leading CROs for preclinical in vivo testing, manufacturing partners, and enthusiastic investors that want to be part of our mission. Please reach out to learn more about ClexBio.

I want to collaborate!
I want to invest!